NCT02619435进行中（未招募）2 期
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study
National Cancer Institute, Naples4 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2015年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
- 试验地点
- 4
- 主要终点
- the rate of evaluable patients alive and not progressed at 6 months
研究概览
简要总结
The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of colorectal adenocarcinoma
- •Any RAS mutation that prevent treatment with anti-EGFR antibodies
- •Measurable disease according to RECIST v. 1.1
- •Disease progression during or following a treatment with fluoropyrimidine, oxaliplatin and bevacizumab, and a treatment with irinotecan is not considered immediately mandatory by the Investigator
- •Age ≥ 18 years
- •ECOG Performance Status 0-1
- •Neutrophils > 1500 / mm3, platelets > 100,000 / mm3, and hemoglobin > 9 g/dL without transfusion or granulocyte-colony stimulating factor (G-CSF) and other hematopoietic growth factors.
- •Bilirubin level < 1.5 x ULN
- •Glomerular filtration rate > 30 mL/min/1.73 m2 according to the Modified Diet in Renal Disease abbreviated formula
- •AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN (≤ 5 x ULN if liver metastasis are present)
- •Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN if liver metastasis are present)
- •Serum creatinine < 1.5 x ULN
- •Amylase and lipase ≤ 1.5 x ULN
- •INR and aPTT ≤ 1.5 x ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no underlying abnormality in coagulation parameters exists per medical history.
- •Understand, be willing to give consent, and sign the written informed consent form (ICF) prior to undergoing any study-specific procedure.
- •If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment.
- •If potentially childbearing female, or if male, agree to use adequate contraception (eg, abstinence, intrauterine device, oral contraceptive, or double-barrier method) from the date on which the ICF is signed until 8 weeks after the last dose of study drug.
- •Life expectancy of greater than 3 months
排除标准
- •Previous treatment with regorafenib or irinotecan
- •Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort)
- •Have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment
- •Have congestive heart failure classified as New York Heart Association Class 2 or higher
- •Have had unstable angina (angina symptoms at rest) or new-onset angina < 3 months prior to screening.
- •Have had a myocardial infarction < 6 months prior to initiation of study treatment.
- •Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin.
- •Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months prior to the initiation of study treatment
- •Symptomatic brain metastases or meningeal tumors
- •Patients with evidence or history of bleeding diathesis
- •Uncontrolled hypertension (systolic blood pressure [SBP] >140 mmHg or diastolic blood pressure [DBP] > 90 mmHg)
- •Have interstitial lung disease with ongoing signs and symptoms at the time informed consent is obtained
- •Have persistent proteinuria > 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (< Grade 3, CTCAE v 4.0).
- •Have unresolved toxicity higher than National Cancer Institute-Common Terminology for Adverse Events version 4.0 (CTCAE v 4.0) Grade 1 attributed to any prior therapy/procedure, excluding alopecia and/or oxaliplatin-induced neurotoxicity ≤ Grade 2 and hemoglobin ≥ 9 g/dL as per inclusion criteria
- •Patients who cannot take oral medication, who require intravenous alimentation, have had prior surgical procedures affecting absorption, or have active peptic ulcer disease
- •Pregnant or lactating women
- •Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer)
- •Any unstable systemic disease (including active infections, any significant hepatic, renal or metabolic disease), metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of regorafenib or render the patient at high risk for treatment complications
- •Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
- •Have any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results.
- •Have a known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs.
- •Have a close affiliation with the investigational site (eg, be a close relative of the investigator) or be a dependent person (eg, be an employee or student working at the investigational site).
研究组 & 干预措施
regorafenib
Experimental
干预措施: regorafenib (Drug)
结局指标
主要结局
the rate of evaluable patients alive and not progressed at 6 months
时间窗: 6 months
次要结局
- worst grade toxicity per patient(every 4 weeks up to 1 year)
- number of patients with complete plus partial response(6 months)
- progression free survival(up to one year)
- overall survival(up to 2 years)
研究者
研究点 (4)
Loading locations...
相似试验
终止
2 期
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus BevacizumabMetastatic DiseaseColorectal NeoplasmsNCT02175654Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)15
已完成
2 期
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal CancerMetastatic DiseaseColorectal NeoplasmsNCT01875380Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)46
进行中（未招募）
1 期
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, single-arm, two-stage, phase 2 study.patients with RAS-mutant advanced colorectal cancerMedDRA version: 21.0Level: LLTClassification code 10038029Term: Rectal adenocarcinoma stage IVSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10001172Term: Adenocarcinoma of colon stage IVSystem Organ Class: 100000004864EUCTR2015-001105-13-ITISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE46
已完成
2 期
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal TumorGastrointestinal Stromal TumorNCT01068769Suzanne George, MD34
已完成
2 期
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal AdenocarcinomaMetastatic Colorectal AdenocarcinomaNCT02023333Memorial Sloan Kettering Cancer Center11